Stocktoria
Galmed Pharmaceuticals Ltd. GLMD
Galmed Pharmaceuticals Ltd. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($11.36); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
Galmed Pharmaceuticals Ltd. trades at about 0.2× earnings — below its 10-year norm (10-year range 0.1×–14.7×, median 0.3×).
Shaded band = 10-year range (0.1×–14.7×); dot = today's 0.2×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | — | — | — | — | — | — | — | -525.8% | -1139.5% | — |
| FCF margin | — | — | — | — | — | — | — | -447.2% | -1113.3% | -2600.9% |
| Return on assets | -55.3% | -40.6% | -41.6% | -107.9% | -88.7% | -54.9% | -26.5% | — | — | — |
| Return on equity | -65.3% | -46.0% | -49.8% | -133.1% | -106.5% | -65.2% | -29.3% | — | — | — |
| Debt / equity | — | — | — | — | — | — | — | — | 0.00× | 0.07× |
| Current ratio | 6.55 | 7.42 | 4.81 | 4.76 | 6.13 | 6.47 | 11.02 | 33.41 | 4.98 | 3.44 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.